e-Therapeutics plc e-therapeutics to present at Shares Evening
May 15 2020 - 9:12AM
RNS Non-Regulatory
TIDMETX
e-Therapeutics plc
15 May 2020
e-therapeutics PLC
e-therapeutics to present at Shares Investor Evening
Oxford, UK, 15 May 2020 - e-therapeutics plc (AIM: ETX.L,
"e-therapeutics" or "the Company") will be presenting at the Shares
Investor Evening - Webinar sponsored by AJ Bell on Tuesday 19(th)
May 2020. The webinar will start at 18:00 BST and investors can
register to attend here:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-190520
Ali Mortazavi, Executive Chairman of e-therapeutics, will be
presenting an overview of the Company and will be available to take
questions during the event.
-Ends-
For more information, please contact:
e-therapeutics plc Tel: +44 (0)1993 883 125
Ali Mortazavi, Executive Chairman www.etherapeutics.co.uk
Laura Roca-Alonso, Chief Business Officer
Numis Securities Limited Tel: +44 (0) 207 260 1000
Freddie Barnfield/Duncan Monteith (Nominated www.numis.com
Adviser)
James Black (Corporate Broking)
FTI Consulting Tel: +44 (0) 203 727 1000
Simon Conway/Stephanie Cuthbert Email: e-therapeutics@fticonsulting.com
About e-therapeutics
e-therapeutics is an Oxford, UK-based company with a unique and
powerful computer-based approach to drug discovery, founded on our
industry-leading expertise in network biology.
We have created two proprietary, unique and productive
technologies. The first is Network-driven Drug Discovery ("NDD"),
which is based on cutting-edge network science, statistics, machine
learning and artificial intelligence. NDD allows the more efficient
discovery of new and better drugs and has been validated in
multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks ("GAINs").
GAINs is a revolutionary and entirely novel approach to functional
genomics, based on the same validated network biology and analytics
expertise that underpins our NDD technologies. GAINs analyses human
genetic data to provide a deep and valuable understanding of the
mechanisms that cause disease. GAINs has the potential to uncover
unrecognised disease processes and pathways and can enable the
discovery of novel drugs, diagnostics and biomarkers in a way not
previously possible from population genomics data, such as
genome-wide association studies ("GWAS").
We have deployed our highly productive drug discovery platform
technologies to develop our own IP-protected, pre-clinical drug
discovery programmes that are available to partners seeking to
acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a
US-based, top 5 pharmaceutical company in neurodegeneration. We are
working on different types of collaborative partnerships with
biotech, pharma and other technology companies to create
sustainable mutual value.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUVRSRRBUVAAR
(END) Dow Jones Newswires
May 15, 2020 10:12 ET (14:12 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024